K.-L.G. Spindler - Concepedia

Author

K.-L.G. Spindler

Also Known As

K. -L. Garm Spindler, K.-L. G. Spindler, K.-L. Garm Spindler, K.-L. Spindler, K.-L.G. Spindler, K.L. Garm Spindler, K.L. Spindler, K.L.G. Spindler, K.‐L. G. Spindler, Karen Lise G. Spindler

Publications

703

Citations

H-Index

Concepts

All Affiliations

Vejle Sygehus Aarhus University Hospital Odense University Hospital Oslo University Hospital University of Oslo

About

K.-L.G. Spindler is an author at Vejle Sygehus specializing in medicine, colorectal cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	364
2	Pathology	6	6	290
3	Surgical Oncology	2	2	99
4	Cancer Genetics	2	2	104
5	Cell Biology	1	1	13

K.-L.G. Spindler

Publications

675

Citations

H-Index

Page 1

	Year	Citations
Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer K.-L.G. Spindler, Niels Pallisgaard, Rikke Fredslund Andersen, PLoS ONE	2015	120
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer K.-L.G. Spindler, Niels Pallisgaard, Audrey Rasmussen, Annals of Oncology Kras MutationsG PolymorphismGastrointestinal OncologyMedicinePathology	2009	75
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial Anna Johnsson, Helga Hagman, Jan‐Erik Frödin, Annals of Oncology Gastrointestinal OncologyMedicineColorectal CancerMetastatic Colorectal CancerBevacizumab Alone	2013	74
Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer Jakob Vasehus Schou, Finn Ole Larsen, Brita Singers Sørensen, Annals of Oncology Surgical OncologyRadiation TherapyMedicinePathologyTreatment Failure	2017	74
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy Julian Hamfjord, Tormod Kyrre Guren, Olav Dajani, Annals of Oncology MedicinePathologyColorectal CancerMetastatic Colorectal CancerCancer Genomics	2019	74
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202) Sheela Rao, Gayathri Anandappa, Jaume Capdevila, ESMO Open	2022	69
The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long‐course preoperative chemoradiotherapy Jan Lindebjerg, K.-L.G. Spindler, Anders Jakobsen Colorectal Disease	2008	48
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer K.-L.G. Spindler, Rikke Fredslund Andersen, Lars Henrik Jensen, Annals of Oncology G PolymorphismFirst-line CapecitabineMedicineColorectal CancerPathology	2009	29
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study Ravit Geva, Loredana Vecchione, Konstantinos T Kalogeras, Gut	2014	27
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer Bengt Glimelius, Michael Lahn, Sulochana R. Gawande, Annals of Oncology Surgical OncologyChemonaive PatientsGastrointestinal OncologyMedicinePathology	2009	25

Page 1